

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralization

Cell

184, 2384-2393.e12

DOI: [10.1016/j.cell.2021.03.036](https://doi.org/10.1016/j.cell.2021.03.036)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Impact of New Variants on SAR-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions. SSRN Electronic Journal, 0, , .	0.4	3
2	Corilagin and 1,3,6-Tri-O-galloyl- β -D-glucose: potential inhibitors of SARS-CoV-2 variants. Physical Chemistry Chemical Physics, 2021, 23, 14873-14888.	1.3	12
3	An overview of current COVID-19 vaccine platforms. Computational and Structural Biotechnology Journal, 2021, 19, 2508-2517.	1.9	99
4	Neutralizing Antibody-Independent SARS-CoV-2 Control Correlated with Intranasal Vaccine-Induced CD8 ⁺ T-Cell Responses. SSRN Electronic Journal, 0, , .	0.4	0
5	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerging Microbes and Infections, 2021, 10, 1097-1111.	3.0	25
8	SARS-CoV-2 vaccination efficacy on hospitalisation and variants. Anaesthesia, Critical Care & Pain Medicine, 2021, , 100867.	0.6	0
14	Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. Microorganisms, 2021, 9, 748.	1.6	14
32	Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B.1.351 Isolates in Microneutralization Assays. Viruses, 2021, 13, 996.	1.5	14
33	Heterogeneity of SARS-CoV-2 virus produced in cell culture revealed by shotgun proteomics and supported by genome sequencing. Analytical and Bioanalytical Chemistry, 2021, 413, 7265-7275.	1.9	7
38	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science, 2021, 373, 818-823.	6.0	309
39	COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nature Medicine, 2021, 27, 1230-1238.	15.2	279
41	Proposal for Tier-Based Resumption of Dental Practice Determined by COVID-19 Rate, Testing and COVID-19 Vaccination: A Narrative Perspective. Journal of Clinical Medicine, 2021, 10, 2116.	1.0	7
47	Review of Current COVID-19 Diagnostics and Opportunities for Further Development. Frontiers in Medicine, 2021, 8, 615099.	1.2	103
48	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. Diagnostics, 2021, 11, 941.	1.3	45
49	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Science Immunology, 2021, 6, .	5.6	455
53	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. Biomedicine, 2021, 9, 611.	1.4	10
54	A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. Vaccines, 2021, 9, 520.	2.1	28
55	Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19 Convalescent Donors. Journal of Immunology, 2021, 206, 2614-2622.	0.4	22

#	ARTICLE	IF	CITATIONS
61	Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants. <i>Vaccines</i> , 2021, 9, 517.	2.1	17
63	A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. <i>MedComm</i> , 2021, 2, 430-441.	3.1	37
66	Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. <i>Diagnostics</i> , 2021, 11, 1190.	1.3	10
68	Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. <i>Journal of Infectious Diseases</i> , 2021, 224, 1109-1114.	1.9	56
71	Landscape and selection of vaccine epitopes in SARS-CoV-2. <i>Genome Medicine</i> , 2021, 13, 101.	3.6	30
72	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22
74	New variants of SARS-CoV-2. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 419-428.	0.5	49
75	Persistence of humoral response upon SARS-CoV-2 infection. <i>Reviews in Medical Virology</i> , 2022, 32, e2272.	3.9	14
76	Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil. <i>Viruses</i> , 2021, 13, 1237.	1.5	23
78	Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants. <i>Frontiers in Medical Technology</i> , 2021, 3, 694347.	1.3	22
79	Ramping Up Antimicrobial Peptides Against Severe Acute Respiratory Syndrome Coronavirus-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 620806.	1.6	28
80	Genome-wide association analysis of COVID-19 mortality risk in SARS-CoV-2 genomes identifies mutation in the SARS-CoV-2 spike protein that colocalizes with P.1 of the Brazilian strain. <i>Genetic Epidemiology</i> , 2021, 45, 685-693.	0.6	14
82	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
84	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. <i>Viruses</i> , 2021, 13, 1192.	1.5	150
86	A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel. <i>Vaccines</i> , 2021, 9, 616.	2.1	25
88	An early assessment of a case fatality risk associated with P.1 SARS-CoV-2 lineage in Brazil: an ecological study. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	5
91	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	6.0	318
94	SARS-CoV-2: An Overview of Virus Genetics, Transmission, and Immunopathogenesis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6312.	1.2	15

#	ARTICLE	IF	CITATIONS
95	Controlling the pandemic during the SARS-CoV-2 vaccination rollout. <i>Nature Communications</i> , 2021, 12, 3674.	5.8	98
96	Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera. <i>Viruses</i> , 2021, 13, 1133.	1.5	19
97	SARS-CoV-2 vaccination efficacy on hospitalisation and variants. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100874.	0.6	2
100	Recent advances in antibody-based immunotherapy strategies for COVID-19. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 1389-1412.	1.2	26
102	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
104	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8
109	Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host. <i>Virus Evolution</i> , 2021, 7, veab061.	2.2	12
110	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
114	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
116	Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. <i>Frontiers in Microbiology</i> , 2021, 12, 701198.	1.5	27
118	Immunosuppression in HIV Positive Heart Transplant Recipients in the post-COVID-19 era. <i>Annals of Thoracic Surgery</i> , 2021, . .	0.7	0
119	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7425.	1.8	69
120	Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONSORT-19 study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 271-281.	2.7	30
121	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. <i>Cell and Bioscience</i> , 2021, 11, 128.	2.1	9
123	Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. <i>Nature Communications</i> , 2021, 12, 4270.	5.8	37
125	SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs. <i>Journal of Evolutionary Biology</i> , 2021, 34, 1867-1877.	0.8	29
126	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC): Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.1	94
127	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	5.1	421

#	ARTICLE	IF	CITATIONS
129	Importance of mutations in amino acid 484 of the Spike protein of SARS-CoV-2: rapid detection by restriction enzyme analysis. <i>Investigacion Clinica</i> , 0, 62, 18-26.	0.0	2
130	Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
132	Conformational Variability Correlation Prediction of Transmissibility and Neutralization Escape Ability for Multiple Mutation SARS-CoV-2 Strains using SSSCPreds. <i>ACS Omega</i> , 2021, 6, 19323-19329.	1.6	6
133	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
134	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
135	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. <i>Science Signaling</i> , 2021, 14, .	1.6	27
136	A novel IgM intranasal intervention against SARS-CoV-2. <i>Antibody Therapeutics</i> , 2021, 4, 171-174.	1.2	4
137	The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. <i>Precision Clinical Medicine</i> , 2021, 4, 149-154.	1.3	7
138	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101606.	0.3	94
139	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
142	Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and Î±OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 719077.	2.2	9
149	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
150	Coronavirus Disease 2019 (COVID-19) Outbreak Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) P.1 Lineage in a Long-Term Care Home After Implementation of a Vaccination Programâ€”Ontario, Canada, Aprilâ€”May 2021. <i>Clinical Infectious Diseases</i> , 2022, 74, 1085-1088.	2.9	27
151	Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. <i>Infection</i> , 2021, 49, 1313-1318.	2.3	10
155	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 288.	7.1	38
157	Copper-Silver Nanohybrids: SARS-CoV-2 Inhibitory Surfaces. <i>Nanomaterials</i> , 2021, 11, 1820.	1.9	20
158	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88
163	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	6.6	190

#	ARTICLE	IF	CITATIONS
164	The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R. <i>Vaccines</i> , 2021, 9, 937.	2.1	12
166	Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model. <i>ACS Infectious Diseases</i> , 2021, 7, 2229-2237.	1.8	12
170	Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1642.	1.5	39
171	SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. <i>MBio</i> , 2021, 12, e0141521.	1.8	33
172	Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. <i>EClinicalMedicine</i> , 2021, 38, 100993.	3.2	43
173	Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2479-2488.	1.8	69
175	Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2455-2456.	4.8	35
176	Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants. <i>Advanced Therapeutics</i> , 2021, 4, 2100099.	1.6	27
177	Data-driven identification of SARS-CoV-2 subpopulations using PhenoGraph and binary-coded genomic data. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	5
178	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
179	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
180	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. <i>Viruses</i> , 2021, 13, 1693.	1.5	69
181	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. <i>ELife</i> , 2021, 10, .	2.8	267
186	mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. <i>Vaccines</i> , 2021, 9, 918.	2.1	40
189	Peptide Platform as a Powerful Tool in the Fight against COVID-19. <i>Viruses</i> , 2021, 13, 1667.	1.5	9
191	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	6.6	46
192	Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. <i>EMBO Journal</i> , 2021, 40, e107985.	3.5	69
193	The rapid adaptation of SARS-CoV-2—rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18

#	ARTICLE	IF	CITATIONS
194	An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. Turkish Journal of Biology, 2021, 45, 342-357.	2.1	3
195	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochemical and Biophysical Research Communications, 2021, 566, 135-140.	1.0	46
196	Opinion on the Policy of Lifting Restrictions to Entry Under the Circumstance of the COVID-19 Pandemic. Infectious Diseases & Immunity, 2021, Publish Ahead of Print, .	0.2	0
197	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology, 2021, 22, 1306-1315.	7.0	57
198	Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity, 2021, 54, 1841-1852.e4.	6.6	114
199	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. Vaccines, 2021, 9, 914.	2.1	20
201	Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy. Open Forum Infectious Diseases, 2021, 8, ofab420.	0.4	12
202	The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein. Virus Evolution, 2021, 7, veab069.	2.2	31
204	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity, 2021, 54, 2399-2416.e6.	6.6	79
205	Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, The, 2021, 374, n2015.	3.0	223
206	Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clinical Microbiology and Infection, 2021, 27, 1109-1117.	2.8	290
207	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Science Immunology, 2021, 6, eabd0205.	5.6	26
208	Back to the past: Are anatomy online classes reminiscent of the anatomy theaters of old?. Anatomical Sciences Education, 2021, 14, 525-527.	2.5	1
209	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Reports, 2021, 37, 109825.	2.9	73
210	A surrogate cell-based SARS-CoV-2 spike blocking assay. European Journal of Immunology, 2021, 51, 2665-2676.	1.6	3
212	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	2.9	80
213	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane Library, 2021, 2021, CD013825.	1.5	114
214	Emerging SARS-CoV-2 variants follow a historical pattern recorded in outgroups infecting non-human hosts. Communications Biology, 2021, 4, 1134.	2.0	3

#	ARTICLE	IF	CITATIONS
215	Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 258-270.	2.7	27
216	The impact of global lineage dynamics, border restrictions, and emergence of the B.1.1.7 lineage on the SARS-CoV-2 epidemic in Norway. Virus Evolution, 2021, 7, veab086.	2.2	6
218	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	6.0	459
219	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports, 2021, 37, 109784.	2.9	20
220	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Molecular Therapy, 2022, 30, 311-326.	3.7	54
224	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Science Advances, 2021, 7, eabj5365.	4.7	83
225	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nature Medicine, 2021, 27, 1518-1524.	15.2	178
226	Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. Frontiers in Immunology, 2021, 12, 729837.	2.2	18
227	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. Frontiers in Immunology, 2021, 12, 752003.	2.2	62
228	Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection. Microbiology Spectrum, 2021, 9, e0089021.	1.2	2
231	Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 34	2.0	19
232	Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Reports, 2021, 36, 109708.	2.9	42
233	The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. Cell, 2021, 184, 5189-5200.e7.	13.5	186
234	Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?. International Immunopharmacology, 2021, 101, 108200.	1.7	20
236	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
237	Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats. Pharmaceutics, 2021, 13, 1519.	2.0	9
238	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. Biomedicines, 2021, 9, 1303.	1.4	87
239	The Role of Nanotechnology in Antiviral Regime: An Overview. Nano LIFE, 0, , 2130011.	0.6	1

#	ARTICLE	IF	CITATIONS
240	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Briefings in Bioinformatics, 2022, 23, .	3.2	16
242	Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. The Lancet Regional Health Americas, 2021, 1, 100025.	1.5	116
243	The Immune Response to SARS-CoV-2 and Variants of Concern. Viruses, 2021, 13, 1911.	1.5	18
244	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nature Communications, 2021, 12, 5652.	5.8	49
245	Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. European Journal of Immunology, 2021, 51, 3202-3213.	1.6	76
246	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Frontiers in Immunology, 2021, 12, 743422.	2.2	10
248	Haematological and radiological-based prognostic markers of COVID-19. Journal of Infection and Public Health, 2021, 14, 1650-1657.	1.9	8
249	Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19. Lancet Microbe, The, 2021, 2, e424.	3.4	11
250	Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5573.	5.8	36
251	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5.	6.6	107
252	Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors Fcγ3RIIA and Fcγ3RIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. MBio, 2021, 12, e0198721.	1.8	57
253	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Frontiers in Cellular and Infection Microbiology, 2021, 11, 690621.	1.8	60
254	Detection of SARS-CoV-2 spike protein D614G mutation by qPCR-HRM analysis. Heliyon, 2021, 7, e07936.	1.4	10
255	Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody. Frontiers in Immunology, 2021, 12, 751584.	2.2	11
256	Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. Journal of Infection, 2021, 83, 467-472.	1.7	28
257	Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets. Current Opinion in Virology, 2021, 50, 139-146.	2.6	7
258	COVID-19, the first pandemic in the post-genomic era. Current Opinion in Virology, 2021, 50, 40-48.	2.6	40
259	Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. International Immunopharmacology, 2021, 99, 108036.	1.7	10

#	ARTICLE	IF	CITATIONS
260	Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2673-2676.	2.0	40
261	Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. <i>Lancet Microbe</i> , The, 2021, 2, e527-e535.	3.4	92
262	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. <i>Journal of Biological Chemistry</i> , 2021, 297, 101151.	1.6	42
263	The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. <i>Journal of Molecular Biology</i> , 2022, 434, 167280.	2.0	92
264	SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112176.	2.5	51
265	Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113789.	2.6	25
266	Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil. <i>One Health</i> , 2021, 13, 100287.	1.5	78
268	Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant. <i>RSC Advances</i> , 2021, 11, 33438-33446.	1.7	3
269	Liquid repellency enabled antipathogen coatings. <i>Materials Today Bio</i> , 2021, 12, 100145.	2.6	7
270	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	3.6	42
271	HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. <i>ELife</i> , 2021, 10, .	2.8	28
272	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2009.	1.5	9
273	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
274	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
275	Imidazoles and benzimidazoles as putative inhibitors of SARS-CoV-2 B.1.1.7 (Alpha) and P.1 (Gamma) variant spike glycoproteins: A computational approach. <i>Chemical Papers</i> , 2021, , 1-11.	1.0	4
276	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2673-2675.	4.8	25
277	mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. <i>ELife</i> , 2021, 10, .	2.8	63
278	Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice. <i>EMBO Molecular Medicine</i> , 2021, 13, e14459.	3.3	25

#	ARTICLE	IF	CITATIONS
279	SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. <i>EMBO Journal</i> , 2021, 40, e108944.	3.5	139
281	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. <i>MSystems</i> , 2021, 6, e0009521.	1.7	26
282	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
283	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
284	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
285	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. <i>Nature Communications</i> , 2021, 12, 6197.	5.8	61
286	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
287	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
288	Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab512.	0.4	11
289	Strategy and Performance Evaluation of Low-Frequency Variant Calling for SARS-CoV-2 Using Targeted Deep Illumina Sequencing. <i>Frontiers in Microbiology</i> , 2021, 12, 747458.	1.5	15
290	Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720357.	1.8	7
291	Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. <i>Vaccines</i> , 2021, 9, 1124.	2.1	3
293	Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant. <i>Biomolecules</i> , 2021, 11, 1494.	1.8	5
294	Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6103.	5.8	117
295	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. <i>Science Advances</i> , 2021, 7, eabj3107.	4.7	23
296	Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. <i>Current Medical Science</i> , 2021, 41, 1065.	0.7	3
297	Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020. <i>Nature Communications</i> , 2021, 12, 6009.	5.8	17
299	Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	17

#	ARTICLE	IF	CITATIONS
300	Evaluation of the clinical and analytical performance of the Seegene allplex [®] , [®] SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI). Journal of Clinical Virology, 2021, 144, 104996.	1.6	16
301	SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement. Antiviral Research, 2021, 195, 105185.	1.9	5
302	Vaccine development and technology for SARS-CoV-2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	2.5	8
303	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science, 2021, 374, 1353-1360.	6.0	246
304	SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability. Journal of Biological Chemistry, 2021, 297, 101371.	1.6	6
305	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 2021, 13, 2177.	1.5	21
306	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Cells, 2021, 10, 2949.	1.8	26
308	Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. Science, 2021, 24, 103393.	1.9	17
309	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. International Journal of Molecular Sciences, 2021, 22, 11869.	1.8	16
310	Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021. Virology, 2022, 565, 29-37.	1.1	7
311	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine, 2021, 39, 7394-7400.	1.7	63
312	Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT [®] , [®] adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. Vaccine: X, 2021, 9, 100126.	0.9	13
313	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). Cell Discovery, 2021, 7, 109.	3.1	17
315	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. Nature Communications, 2021, 12, 6304.	5.8	42
316	Strategy to Develop and Evaluate a Multiplex RT-ddPCR in Response to SARS-CoV-2 Genomic Evolution. Current Issues in Molecular Biology, 2021, 43, 1937-1949.	1.0	9
317	Antibody Dynamics and Durability in Coronavirus Disease-19. Clinics in Laboratory Medicine, 2022, 42, 85-96.	0.7	16
318	Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. Innovation(China), 2022, 3, 100181.	5.2	8
319	Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage. Virus Research, 2022, 308, 198629.	1.1	6

#	ARTICLE	IF	CITATIONS
320	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses " are we our own worst enemy?. Nature Reviews Immunology, 2022, 22, 47-56.	10.6	118
321	Spike residue 403 affects binding of coronavirus spikes to human ACE2. Nature Communications, 2021, 12, 6855.	5.8	25
322	Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Frontiers in Immunology, 2021, 12, 772240.	2.2	33
323	Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host and Microbe, 2021, 29, 1738-1743.e4.	5.1	61
324	When Do We Need Massive Computations to Perform Detailed COVID-19 Simulations?. Advanced Theory and Simulations, 2022, 5, 2100343.	1.3	8
325	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nature Communications, 2021, 12, 6871.	5.8	147
328	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. Archives of Virology, 2022, 167, 293-305.	0.9	28
333	EpiCurator: an immunoinformatic workflow to predict and prioritize SARS-CoV-2 epitopes. PeerJ, 2021, 9, e12548.	0.9	4
334	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. Journal of Experimental Medicine, 2022, 219, .	4.2	46
336	Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. Current Opinion in Pharmacology, 2022, 62, 64-73.	1.7	29
337	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. Microbiology Spectrum, 2021, 9, e0109621.	1.2	39
338	Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. Journal of Medical Virology, 2022, 94, 1300-1314.	2.5	32
340	Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host and Microbe, 2021, 29, 1788-1801.e6.	5.1	145
341	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill "An interim analysis of a nationwide cohort study. PLoS ONE, 2021, 16, e0258704.	1.1	12
344	12-month SARS-CoV-2 antibody persistency in a Tyrolean COVID-19 cohort. Wiener Klinische Wochenschrift, 2021, 133, 1265-1271.	1.0	2
345	SARS-CoV-2 spike evolutionary behaviors; simulation of N501Y mutation outcomes in terms of immunogenicity and structural characteristic. Journal of Cellular Biochemistry, 2022, 123, 417-430.	1.2	9
346	Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States. Transfusion, 2022, 62, 483-492.	0.8	2
347	SARS-CoV-2 introduction and lineage dynamics across three epidemic peaks in Southern Brazil: massive spread of P.1. Infection, Genetics and Evolution, 2021, 96, 105144.	1.0	14

#	ARTICLE	IF	CITATIONS
348	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
349	Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. <i>Microbiology Spectrum</i> , 2021, 9, e0056121.	1.2	15
350	Antibacterial and antiviral high-performance nanosystems to mitigate new SARS-CoV-2 variants of concern. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100363.	1.8	41
351	Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. <i>Genes and Diseases</i> , 2022, 9, 1290-1300.	1.5	13
352	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. <i>Journal of Functional Foods</i> , 2021, 87, 104850.	1.6	23
353	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	2
354	The adaptation of SARS-CoV-2 to humans. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210127.	0.8	4
356	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. <i>Cell Reports</i> , 2022, 38, 110210.	2.9	96
357	Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers. <i>Journal of Infection and Public Health</i> , 2022, 15, 182-186.	1.9	22
358	Comparative mutational analysis of SARS-CoV-2 isolates from Pakistan and structural-functional implications using computational modelling and simulation approaches. <i>Computers in Biology and Medicine</i> , 2022, 141, 105170.	3.9	15
359	From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. <i>Gene</i> , 2022, 814, 146134.	1.0	97
360	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
361	Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ TĀcell responses. <i>Cell Reports Medicine</i> , 2022, 3, 100520.	3.3	29
362	The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1351.	1.8	32
363	Comparative Analysis of Five Multiplex RT-PCR Assays in the Screening of SARS-CoV-2 Variants. <i>Microorganisms</i> , 2022, 10, 306.	1.6	19
364	Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 17-32.	2.9	10
365	Durability of immune responses to the BNT162b2 mRNA vaccine. <i>Med</i> , 2022, 3, 25-27.	2.2	33
366	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq1 1 0.784314 rgBT. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 636-648.	4.6	52

#	ARTICLE	IF	CITATIONS
367	Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	54
368	Experimental Models of COVID-19. Frontiers in Cellular and Infection Microbiology, 2021, 11, 792584.	1.8	27
369	Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. Nature Chemical Biology, 2022, 18, 342-351.	3.9	63
370	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Cell Reports, 2022, 38, 110218.	2.9	148
372	The ins and outs of SARS-CoV-2 variants of concern (VOCs). Archives of Virology, 2022, 167, 327-344.	0.9	35
373	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	2.2	176
374	Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia. Vaccines, 2022, 10, 180.	2.1	17
376	Unbinding ligands from SARS-CoV-2 Mpro via umbrella sampling simulations. Royal Society Open Science, 2022, 9, 211480.	1.1	9
377	The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Cellular and Molecular Life Sciences, 2022, 79, 65.	2.4	29
378	Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. Vaccines, 2022, 10, 82.	2.1	16
379	Apigenin analogues as SARS-CoV-2 main protease inhibitors: <i>In-silico</i> screening approach. Bioengineered, 2022, 13, 3350-3361.	1.4	18
380	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell Reports Medicine, 2022, 3, 100528.	3.3	6
382	Endogenous viral mutations, evolutionary selection, and containment policy design. Journal of Economic Interaction and Coordination, 2022, 17, 801-825.	0.4	4
383	Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China. BMC Medicine, 2022, 20, 37.	2.3	10
384	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. Frontiers in Medicine, 2021, 8, 836826.	1.2	15
385	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. Frontiers in Cellular and Infection Microbiology, 2021, 11, 781429.	1.8	154
386	Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases. Journal of Virology, 2022, 96, jvi0218621.	1.5	30
387	Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?. Vox Sanguinis, 2022, 117, 641-646.	0.7	8

#	ARTICLE	IF	CITATIONS
388	Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M ^{pro} . RSC Advances, 2022, 12, 3729-3737.	1.7	19
391	Plastic Antibodies Mimicking the ACE2 Receptor for Selective Binding of SARS-CoV-2 Spike. Advanced Materials Interfaces, 2022, 9, 2101925.	1.9	12
392	Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus. Frontiers in Medicine, 2021, 8, 793437.	1.2	4
393	Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine. Life, 2022, 12, 57.	1.1	6
394	Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis. Scientific Reports, 2022, 12, 1128.	1.6	28
395	A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. Cell Reports, 2022, 38, 110256.	2.9	19
396	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine, 2022, 75, 103761.	2.7	104
397	Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021. Frontiers in Medicine, 2021, 8, 815870.	1.2	8
398	Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. IScience, 2022, 25, 103659.	1.9	16
401	Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Viruses, 2022, 14, 230.	1.5	1
402	Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduction and Targeted Therapy, 2022, 7, 26.	7.1	139
403	mRNA Covid-19 vaccines in pregnancy: A systematic review. PLoS ONE, 2022, 17, e0261350.	1.1	50
404	Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature, 2022, 603, 700-705.	13.7	447
405	Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures. Life Science Alliance, 2022, 5, e202101116.	1.3	10
406	Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine, 2022, 76, 103818.	2.7	14
407	501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations. Computational Biology and Chemistry, 2022, 97, 107636.	1.1	1
409	SARS-CoV-2 Variant Determination Through SNP Assays in Samples From Industry Workers From Rio de Janeiro, Brazil. Frontiers in Microbiology, 2021, 12, 757783.	1.5	3
410	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. Science Immunology, 2022, 7, .	5.6	28

#	ARTICLE	IF	CITATIONS
411	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
413	Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, 811004.	1.2	3
414	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. <i>Cell</i> , 2022, 185, 447-456.e11.	13.5	736
415	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
417	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	20
418	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
419	Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility—Arizona, 2021. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 960-967.	1.3	4
420	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 44.	7.1	31
421	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
422	Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19. <i>Viruses</i> , 2022, 14, 353.	1.5	11
423	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 766821.	2.2	15
425	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
426	Rapid characterization of spike variants via mammalian cell surface display. <i>Molecular Cell</i> , 2021, 81, 5099-5111.e8.	4.5	32
427	Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. <i>Nature Communications</i> , 2021, 12, 7345.	5.8	58
428	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021, 6, 146.	2.9	14
429	Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. <i>Nature</i> , 2022, 602, 307-313.	13.7	79
432	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29
434	Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 420.	7.1	46

#	ARTICLE	IF	CITATIONS
435	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. International Journal of Biological Sciences, 2022, 18, 1844-1851.	2.6	34
436	Impaired Humoral Immunity Is Associated With Prolonged COVID-19 Despite Robust CD8 T-Cell Responses. SSRN Electronic Journal, 0, , .	0.4	0
437	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opinion on Investigational Drugs, 2022, 31, 41-58.	1.9	26
438	A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Frontiers in Immunology, 2022, 13, 844837.	2.2	13
439	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. MBio, 2022, 13, e0322721.	1.8	48
440	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. Npj Vaccines, 2022, 7, 23.	2.9	6
441	SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science, 2022, 375, 782-787.	6.0	60
443	Neutralization of SARS-CoV-2 Variants by rVSV- $\hat{\Gamma}$ G-Spike-Elicited Human Sera. Vaccines, 2022, 10, 291.	2.1	19
444	Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. Cell Discovery, 2022, 8, 16.	3.1	18
445	An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nature Immunology, 2022, 23, 423-430.	7.0	38
446	Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 2022, 13, 822159.	2.2	19
447	Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry. Clinical Chemistry and Laboratory Medicine, 2022, 60, 941-951.	1.4	13
448	Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City. Viruses, 2022, 14, 545.	1.5	23
449	Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting. PLoS ONE, 2022, 17, e0266086.	1.1	6
450	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. Medical Microbiology and Immunology, 2022, 211, 79-103.	2.6	9
451	Structure/Function Analysis of Truncated Amino-Terminal ACE2 Peptide Analogs That Bind to SARS-CoV-2 Spike Glycoprotein. Molecules, 2022, 27, 2070.	1.7	3
452	SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe, The, 2022, 3, e348-e356.	3.4	107
453	Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice. Journal of Medical Virology, 2022, 94, 3223-3232.	2.5	12

#	ARTICLE	IF	CITATIONS
454	Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants. <i>JCI Insight</i> , 2022, 7, .	2.3	10
455	A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 103960.	1.9	16
457	Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. <i>Frontiers in Medical Technology</i> , 2022, 4, 867982.	1.3	11
458	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. <i>Frontiers in Immunology</i> , 2022, 13, 836232.	2.2	15
459	Rapid Degradation of SARS-CoV-2 Spike S Protein by A Specific Serine Protease. <i>Molecules</i> , 2022, 27, 1882.	1.7	1
460	Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant. <i>Viruses</i> , 2022, 14, 650.	1.5	10
461	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
462	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. <i>IScience</i> , 2022, 25, 103939.	1.9	32
463	Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864.	0.4	5
464	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. <i>Vaccines</i> , 2022, 10, 469.	2.1	8
465	Rapid and Quantitative <i>In Vitro</i> Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies. <i>Analytical Chemistry</i> , 2022, 94, 4504-4512.	3.2	3
466	Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2022, 17, e0265453.	1.1	8
467	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	3.4	48
468	Differential T cell immunity to SARS-CoV-2 in mRNA-1273 and BNT162b2 vaccinated individuals. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	6
469	Virus blocking textile for SARS-CoV-2 using human body triboelectric energy harvesting. <i>Cell Reports Physical Science</i> , 2022, 3, 100813.	2.8	9
471	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10
472	Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 531-546.	2.5	5
473	A multipeptide SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	49

#	ARTICLE	IF	CITATIONS
474	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, 3884.	1.6	11
476	Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 21, 100440.	1.3	5
477	CHARM: COVID-19 Health Action Response for Marines—Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test. <i>PLoS ONE</i> , 2022, 17, e0266691.	1.1	1
478	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
479	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
480	A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 114.	7.1	17
481	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	2.2	10
482	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. <i>Clinical Immunology</i> , 2022, 238, 108999.	1.4	10
484	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell—cell fusion, and neutralization sensitivity. <i>Emerging Microbes and Infections</i> , 2022, 11, 1024-1036.	3.0	5
485	ABO blood groups and the risk of SARS-CoV-2 infection. <i>Protoplasma</i> , 2022, 259, 1381-1395.	1.0	5
486	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	2.5	22
487	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	4.8	50
488	CRISPR-Cas13a cascade-based viral RNA assay for detecting SARS-CoV-2 and its mutations in clinical samples. <i>Sensors and Actuators B: Chemical</i> , 2022, 362, 131765.	4.0	23
489	Emerging SARS-CoV-2 Genotypes Show Different Replication Patterns in Human Pulmonary and Intestinal Epithelial Cells. <i>Viruses</i> , 2022, 14, 23.	1.5	16
494	MicroRNA-Mediated Regulation of the Virus Cycle and Pathogenesis in the SARS-CoV-2 Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13192.	1.8	10
496	Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. <i>PLoS Pathogens</i> , 2021, 17, e1010106.	2.1	12
498	Capturing adaptive immunity against SARS-CoV-2 in patients with cancer. <i>Nature Cancer</i> , 2021, 2, 1298-1300.	5.7	2
500	HLA-A*02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. <i>Cell Reports</i> , 2021, 37, 110167.	2.9	18

#	ARTICLE	IF	CITATIONS
501	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
502	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
509	Mortality and case fatality rates of covid-19 in the state of goi�s, brazil. <i>Journal of Human Growth and Development</i> , 2021, 31, 521-532.	0.2	1
510	Chimeric crRNA improves CRISPR�Cas12a specificity in the N501Y mutation detection of Alpha, Beta, Gamma, and Mu variants of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0261778.	1.1	6
511	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
513	Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together. <i>Frontiers in Immunology</i> , 2021, 12, 790469.	2.2	15
514	Coronavirus Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 101-121.	0.8	3
515	Broad-spectrum Respiratory Virus Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 137-153.	0.8	2
516	DeepSARS: simultaneous diagnostic detection and genomic surveillance of SARS-CoV-2. <i>BMC Genomics</i> , 2022, 23, 289.	1.2	5
517	Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 868020.	2.2	3
518	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
519	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	1.8	20
520	Nasally delivered interferon-� protects mice against infection by SARS-CoV-2 variants including Omicron. <i>Cell Reports</i> , 2022, 39, 110799.	2.9	39
521	Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. <i>Journal of Virology</i> , 2022, 96, e0038922.	1.5	5
522	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. <i>Cell Reports</i> , 2022, 39, 110754.	2.9	5
523	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
524	Development of antibody resistance in emerging mutant strains of SARS CoV�2: Impediment for COVID�19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
525	Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction. <i>Cell Research</i> , 2022, 32, 593-595.	5.7	55

#	ARTICLE	IF	CITATIONS
526	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. <i>Molecular Therapy</i> , 2022, 30, 2968-2983.	3.7	20
528	Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccinated Immunized Plasma. <i>Advanced Science</i> , 2022, 9, e2104333.	5.6	8
530	Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0017822.	1.8	15
531	Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program. <i>BMC Infectious Diseases</i> , 2022, 22, 404.	1.3	24
532	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. <i>Science Immunology</i> , 2021, , eabl5652.	5.6	6
533	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
534	Multiplex Fragment Analysis for Flexible Detection of All SARS-CoV-2 Variants of Concern. <i>Clinical Chemistry</i> , 2022, 68, 1042-1052.	1.5	12
535	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. <i>Viruses</i> , 2022, 14, 854.	1.5	5
536	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24
537	Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. <i>Virology Journal</i> , 2022, 19, 76.	1.4	61
538	Photonics enabled intelligence system to identify SARS-CoV 2 mutations. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 3321-3336.	1.7	11
539	Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2201433119.	3.3	19
540	Detection of Major SARS-CoV-2 Variants of Concern in Clinical Samples via CRISPR-Cas12a-Mediated Mutation-Specific Assay. <i>ACS Synthetic Biology</i> , 2022, 11, 1811-1823.	1.9	9
541	Comparing the Nucleocapsid Proteins of Human Coronaviruses: Structure, Immunoregulation, Vaccine, and Targeted Drug. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 761173.	1.6	10
542	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. <i>Translational Research</i> , 2022, 248, 11-21.	2.2	13
543	Pilot Investigation of SARS-CoV-2 Variants in the Island of Sicily Prior to and in the Second Wave of the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 869559.	1.5	2
545	Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. <i>Biomedicines</i> , 2022, 10, 996.	1.4	3
546	Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Transfusion Medicine and Hemotherapy</i> , 2022, 49, 388-400.	0.7	3

#	ARTICLE	IF	CITATIONS
547	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
548	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	2.9	287
549	COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants. <i>Scientific Reports</i> , 2022, 12, 7168.	1.6	15
550	Association of Gut Microbiota with Inflammatory Bowel Disease and COVID-19 Severity: A Possible Outcome of the Altered Immune Response. <i>Current Microbiology</i> , 2022, 79, 184.	1.0	8
551	Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients. <i>Communications Biology</i> , 2022, 5, 409.	2.0	5
552	Macromolecular Viral Entry Inhibitors as Broadâ€Spectrum Firstâ€Line Antivirals with Activity against SARSâ€CoVâ€2. <i>Advanced Science</i> , 2022, 9, e2201378.	5.6	8
553	Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 â€ A Comprehensive Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 841009.	2.2	0
554	ADAM10 and ADAM17 promote SARSâ€CoVâ€2 cell entry and spike proteinâ€mediated lung cell fusion. <i>EMBO Reports</i> , 2022, 23, e54305.	2.0	57
555	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120976119.	3.3	27
556	Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2118312119.	3.3	86
557	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. <i>Cell Host and Microbe</i> , 2022, 30, 1103-1111.e6.	5.1	38
558	Emerging SARS-CoV-2 variants: Why, how, and what's next?. , 2022, 1, 100029.		26
559	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. <i>Molecular Therapy</i> , 2022, 30, 2952-2967.	3.7	2
560	Massively multiplexed affinity characterization of therapeutic antibodies against SARS-CoV-2 variants. <i>Antibody Therapeutics</i> , 2022, 5, 130-137.	1.2	5
561	Managing an evolving pandemic: Cryptic circulation of the Delta variant during the Omicron rise. <i>Science of the Total Environment</i> , 2022, 836, 155599.	3.9	24
563	Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants. <i>Cell and Bioscience</i> , 2022, 12, 63.	2.1	4
564	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. <i>EBioMedicine</i> , 2022, 80, 104062.	2.7	10
565	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2

#	ARTICLE	IF	CITATIONS
567	A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. <i>Journal of Medical Virology</i> , 2022, 94, 4287-4293.	2.5	13
568	SARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5. <i>Nature Communications</i> , 2022, 13, .	5.8	32
569	Engineered Soluble ACE2 Protein and SARS-CoV-2 Variants of Concern (VOCs). <i>Coronaviruses</i> , 2022, 03, .	0.2	0
572	Human interaction targets of SARS-CoV-2 spike protein: A systematic review. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2210953.	0.2	3
573	Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection. <i>Nature Aging</i> , 0, , .	5.3	4
574	Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. <i>Cancer Cell</i> , 2022, 40, 738-753.e5.	7.7	19
577	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
578	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
579	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
580	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
581	Recent insights into SARS-CoV-2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	29
582	Withasomniferol C, a new potential SARS-CoV-2 main protease inhibitor from the <i>Withania somnifera</i> plant proposed by <i>in silico</i> approaches. <i>PeerJ</i> , 0, 10, e13374.	0.9	4
583	Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	5
584	Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 874.	2.1	5
585	SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
586	The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	19
587	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1232.	1.5	2
588	Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. <i>Viruses</i> , 2022, 14, 1349.	1.5	7

#	ARTICLE	IF	CITATIONS
589	Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression. <i>Viruses</i> , 2022, 14, 1308.	1.5	1
590	Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. <i>Science Immunology</i> , 2022, 7, .	5.6	89
593	ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2022, 14, 1326.	1.5	4
594	Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant. <i>Clinics</i> , 2022, 77, 100068.	0.6	2
595	A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. <i>Future Virology</i> , 0, , .	0.9	4
596	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	1.5	30
597	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. <i>Nature Communications</i> , 2022, 13, .	5.8	22
598	Multiplex Quantitative Polymerase Chain Reaction Test to Identify SARS-CoV-2 Variants. <i>Methods in Molecular Biology</i> , 2022, , 67-78.	0.4	1
599	An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry. <i>Emerging Microbes and Infections</i> , 2022, 11, 1920-1935.	3.0	7
600	The nervous system during COVID-19: Caught in the crossfire. <i>Immunological Reviews</i> , 2022, 311, 90-111.	2.8	9
602	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
603	Introduction and Establishment of SARS-CoV-2 Gamma Variant in New York City in Early 2021. <i>Journal of Infectious Diseases</i> , 2022, 226, 2142-2149.	1.9	5
604	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
605	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
606	A new strategy: identification of specific antibodies for neutralizing epitope on SARS-CoV-2 S protein by LC-MS/MS combined with immune repertoire. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	1
607	Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. <i>Communications Biology</i> , 2022, 5, .	2.0	6
608	A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action. <i>Proteomics</i> , 0, , 2200118.	1.3	3
609	Monoclonal antibody therapies against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e311-e326.	4.6	114

#	ARTICLE	IF	CITATIONS
610	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <i>Current Pharmaceutical Design</i> , 2022, 28, 2901-2913.	0.9	3
611	Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. <i>Nature Communications</i> , 2022, 13, .	5.8	53
612	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5707-5727.	2.0	7
613	Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
615	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	1.9	16
616	A Retinol Derivative Inhibits SARS-CoV-2 Infection by Interrupting Spike-Mediated Cellular Entry. <i>MBio</i> , 2022, 13, .	1.8	14
617	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
618	Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species. <i>PLoS Pathogens</i> , 2022, 18, e1010618.	2.1	5
619	Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and Î±-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine. <i>Pharmaceutics</i> , 2022, 14, 1455.	2.0	3
620	Genetic Surveillance of SARS-CoV-2 M ^{pro} Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid. <i>MBio</i> , 2022, 13, .	1.8	40
621	Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
622	SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. <i>Emerging Microbes and Infections</i> , 2022, 11, 1819-1827.	3.0	10
623	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	2.7	128
624	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>IScience</i> , 2022, 25, 104705.	1.9	8
625	Rapid and qualitative identification of SARS-CoV-2 mutations associated with variants of concern using a multiplex RT-PCR assay coupled with melting analysis. <i>International Journal of Infectious Diseases</i> , 2022, 122, 401-404.	1.5	5
626	Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy. <i>Pathogens</i> , 2022, 11, 823.	1.2	14
627	The trispesific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. <i>Nature Biotechnology</i> , 2022, 40, 1845-1854.	9.4	25
628	Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2. <i>Npj Vaccines</i> , 2022, 7, .	2.9	7

#	ARTICLE	IF	CITATIONS
629	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8177.	1.8	5
630	Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4501-4516.	1.9	8
631	Genomic evidence for divergent co-infections of co-circulating SARS-CoV-2 lineages. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4015-4024.	1.9	14
632	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
633	Molecular adaptations during viral epidemics. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
634	High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020â€“2021. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
635	The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
636	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
637	Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	9
638	Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease. <i>MBio</i> , 0, , .	1.8	3
639	SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients â€“ a comparative long term post-infection study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
640	Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies. <i>Communications Biology</i> , 2022, 5, .	2.0	5
641	Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: Allosteric communications between and within viral and human proteins. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4562-4578.	1.9	3
642	COVID-19 hastalarÄ±nda varyantlarÄ±n ve aÄŸÄ±larÄ±n prognoza etkisi: Retrospektif gÄ±zlemsel ÅšalÄ±ÅŸma. <i>Anadolu KliniÄŸi TÄ±p Bilimleri Dergisi</i> , 0, , .	0.1	0
643	Effectiveness of Household Disinfection Techniques to Remove SARS-CoV-2 from Cloth Masks. <i>Pathogens</i> , 2022, 11, 916.	1.2	2
644	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <i>Journal of Virology</i> , 2022, 96, .	1.5	14
645	BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	29
647	Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. <i>Pharmaceuticals</i> , 2022, 15, 1002.	1.7	3

#	ARTICLE	IF	CITATIONS
648	Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	3
649	SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
650	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
651	The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
653	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
656	Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
657	Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. <i>Vaccines</i> , 2022, 10, 1251.	2.1	10
658	Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2. <i>Structure</i> , 2022, 30, 1432-1442.e4.	1.6	18
659	A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination. <i>Nature Nanotechnology</i> , 2022, 17, 993-1003.	15.6	58
660	Nanotechnology-based strategies against SARS-CoV-2 variants. <i>Nature Nanotechnology</i> , 2022, 17, 1027-1037.	15.6	63
661	Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. <i>Virus Research</i> , 2022, 319, 198882.	1.1	10
662	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
663	Searching for potential inhibitors of SARS-COV-2 main protease using supervised learning and perturbation calculations. <i>Chemical Physics</i> , 2023, 564, 111709.	0.9	6
664	Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7144-7157.	2.0	2
665	The role of B cells in COVID-19 infection and vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	25
666	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <i>Cell</i> , 2022, 185, 4008-4022.e14.	13.5	55
667	The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
671	Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. <i>Vaccine</i> , 2022, , .	1.7	3

#	ARTICLE	IF	CITATIONS
672	The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. <i>IScience</i> , 2022, 25, 105016.	1.9	2
673	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
675	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
676	Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
677	Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	13
678	A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques. <i>Frontiers in Plant Science</i> , 0, 13, .	1.7	3
679	Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 1041-1054.	4.0	4
680	The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. <i>Drug Resistance Updates</i> , 2022, 65, 100882.	6.5	31
681	IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, .	5.8	5
682	Newly-onset Autoimmune Diabetes Mellitus Triggered by COVID 19 Infection: A Case-based Review. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, 887-893.	0.6	4
684	Dynamics of SARS-CoV-2 lineages in French Guiana in 2020â€“2021: 4 epidemic waves with cross-influences from Europe and South America. <i>Infection, Genetics and Evolution</i> , 2022, 105, 105370.	1.0	1
685	Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	0.6	0
686	Spike protein mediated membrane fusion during SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	15
687	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0263861.	1.1	12
688	Rapid and convenient detection of SARS-CoV-2 using a colorimetric triple-target reverse transcription loop-mediated isothermal amplification method. <i>PeerJ</i> , 0, 10, e14121.	0.9	0
689	Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 979-991.	1.4	2
690	A Simplified Sanger Sequencing Method for Detection of Relevant SARS-CoV-2 Variants. <i>Diagnostics</i> , 2022, 12, 2609.	1.3	2
691	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4

#	ARTICLE	IF	CITATIONS
692	Influenza Infection in Ferrets with SARS-CoV-2 Infection History. <i>Microbiology Spectrum</i> , 0, , .	1.2	0
693	Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
694	Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. <i>Virologica Sinica</i> , 2022, 37, 831-841.	1.2	2
695	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
696	A Vaccine with Multiple Receptor-Binding Domain Subunit Mutations Induces Broad-Spectrum Immune Response against SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 1653.	2.1	1
697	SARS-CoV-2 evolves to reduce but not abolish neutralizing action. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
698	Use of natural cysteine protease inhibitors in limiting SARS-Co-2 fusion into human respiratory cells. <i>Medical Hypotheses</i> , 2022, 168, 110965.	0.8	0
699	Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
700	Multiple partition Markov model for B.1.1.7, B.1.351, B.1.617.2, and P.1 variants of SARS-CoV 2 virus. <i>Computational Statistics</i> , 0, , .	0.8	1
701	Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides. <i>Antiviral Research</i> , 2022, 208, 105445.	1.9	9
702	The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14057.	1.8	4
703	A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8
704	Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models. <i>IScience</i> , 2022, 25, 105596.	1.9	8
705	Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1. <i>Viruses</i> , 2022, 14, 2475.	1.5	0
706	Antibody multispecificity: A necessary evil?. <i>Molecular Immunology</i> , 2022, 152, 153-161.	1.0	4
707	A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	5
708	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. <i>Scientific Reports</i> , 2022, 12, .	1.6	17
709	A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant. <i>Plant Biotechnology Journal</i> , 2023, 21, 549-559.	4.1	8

#	ARTICLE	IF	CITATIONS
710	Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern. <i>Vaccines</i> , 2022, 10, 1962.	2.1	4
711	An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
713	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
714	Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
715	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
716	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
717	Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics. <i>Journal of Molecular Biology</i> , 2023, 435, 167928.	2.0	24
718	Genome Evolution and Early Introductions of the SARS-CoV-2 Omicron Variant in Mexico. <i>Virus Evolution</i> , 2022, 8, .	2.2	3
719	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. <i>International Immunology</i> , 2023, 35, 213-220.	1.8	6
720	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
721	Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 212-222.	1.5	9
722	Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
723	SARS-CoV-2 Lineage P.4 Detection in Southeast Brazil: A Retrospective Genomic and Clinical Overview. <i>Covid</i> , 2022, 2, 1768-1777.	0.7	1
725	A bivalent subunit vaccine efficiently produced in <i>Pichia pastoris</i> against SARS-CoV-2 and emerging variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
727	Genome Structure, Life Cycle, and Taxonomy of Coronaviruses and the Evolution of SARS-CoV-2. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 305-339.	0.7	3
728	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. <i>Cell Discovery</i> , 2023, 9, .	3.1	11
729	Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
730	TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection. <i>Viruses</i> , 2023, 15, 271.	1.5	24

#	ARTICLE	IF	CITATIONS
731	S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 193.	2.1	1
732	A perspective on SARS-CoV-2 virus-like particles vaccines. <i>International Immunopharmacology</i> , 2023, 115, 109650.	1.7	6
733	Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants. <i>Vaccine</i> , 2022, , .	1.7	1
735	The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
736	Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. <i>Vaccines</i> , 2023, 11, 58.	2.1	5
737	Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	1
738	Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. <i>Viral Immunology</i> , 0, , .	0.6	1
739	Visualized RNA detection of SARS-CoV-2 in a closed tube by coupling RT-PCR with nested invasive reaction. <i>Analyst</i> , The, 0, , .	1.7	0
740	Viral immunity: Basic mechanisms and therapeutic applicationsâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1521, 32-45.	1.8	0
741	State of the art in epitope mapping and opportunities in COVID-19. <i>Future Science OA</i> , 2023, 9, .	0.9	4
742	An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. <i>Progress in Biophysics and Molecular Biology</i> , 2023, 178, 32-49.	1.4	16
743	CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern. <i>Biosensors and Bioelectronics</i> , 2023, 229, 115238.	5.3	6
744	Antibody isotype epitope mapping of SARSâ€“CoVâ€“2 Spike RBD protein: Targets for COVIDâ€“19 symptomatology and disease control. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	2
745	Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2. <i>Antiviral Research</i> , 2023, 211, 105541.	1.9	2
746	Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic. <i>Genes</i> , 2023, 14, 407.	1.0	10
747	Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
748	Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. <i>Antibody Therapeutics</i> , 2023, 6, 76-86.	1.2	0
749	Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0

#	ARTICLE	IF	CITATIONS
750	Evaluating Data Sharing of SARS-CoV-2 Genomes for Molecular Epidemiology across the COVID-19 Pandemic. <i>Viruses</i> , 2023, 15, 560.	1.5	2
751	A computational map of the human-SARS-CoV-2 protein-RNA interactome predicted at single-nucleotide resolution. <i>NAR Genomics and Bioinformatics</i> , 2023, 5, .	1.5	3
752	Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. <i>Nature Methods</i> , 2023, 20, 512-522.	9.0	111
753	Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	1
754	Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants. <i>Nature Communications</i> , 2023, 14, .	5.8	8
755	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 161, 117000.	5.8	11
756	A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
757	ZnO-Based Electrochemical Immunosensor to Assess Vaccine-Induced Antibody-Mediated Immunity against Wild-Type and Gamma SARS-CoV-2 Strains. <i>Biosensors</i> , 2023, 13, 371.	2.3	3
758	Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
759	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
760	Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
762	Identification of SARS CoV-2 Omicron BA.1 and a novel Delta lineage by rapid methods and partial spike protein sequences in Sulaymaniyah Province, Iraq. <i>Immunity, Inflammation and Disease</i> , 2023, 11, .	1.3	0
763	Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. <i>Nature Communications</i> , 2023, 14, .	5.8	6
764	Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	4
765	The origins of new SARS-COV-2 variants in immunocompromised individuals. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 148-156.	1.5	3
766	Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System. <i>Vaccines</i> , 2023, 11, 771.	2.1	4
768	The evolution of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2023, 21, 361-379.	13.6	239
769	Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence. <i>Cell Reports</i> , 2023, 42, 112421.	2.9	3

#	ARTICLE	IF	CITATIONS
770	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nature Communications, 2023, 14, .	5.8	12
771	Combination of Recombinant Proteins S1/N and RBD/N as Potential Vaccine Candidates. Vaccines, 2023, 11, 864.	2.1	1
779	Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	15
790	The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern. Advances in Experimental Medicine and Biology, 2023, , 3-26.	0.8	0
813	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
830	Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants. , 0, , .		0